Vyne Therapeutics Inc
NASDAQ:VYNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vyne Therapeutics Inc
Net Income (Common)
Vyne Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vyne Therapeutics Inc
NASDAQ:VYNE
|
Net Income (Common)
-$26.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$21B
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$26.3m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$8.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$25.3B
|
CAGR 3-Years
64%
|
CAGR 5-Years
33%
|
CAGR 10-Years
27%
|
|
Vyne Therapeutics Inc
Glance View
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.
See Also
What is Vyne Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-26.5m
USD
Based on the financial report for Dec 31, 2025, Vyne Therapeutics Inc's Net Income (Common) amounts to -26.5m USD.
What is Vyne Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
36%
Over the last year, the Net Income (Common) growth was 34%. The average annual Net Income (Common) growth rates for Vyne Therapeutics Inc have been -4% over the past three years , 36% over the past five years .
